High Dose Cytarabine plus Gemtuzumab Ozogamicin for Patients with Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3 g/m(2) over 3 hours daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9 mg/m(2) on day 7 and 4.5 mg/m(2) on day 14 was not tolerated, but HiDAC followed by...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stone, Richard M., Moser, Barry, Sanford, Ben, Schulman, Philip, Kolitz, Jonathan E., Allen, Steven, Stock, Wendy, Galinsky, Ilene, Vij, Ravi, Marcucci, Guido, Hurd, David, Larson, Richard A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3023007/
https://ncbi.nlm.nih.gov/pubmed/20688393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2010.07.017
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak